About Carragelose
Carragelose is a company based in Korneuburg (Austria) founded in 2007 was acquired by Nicox in September 2014. Carragelose offers products and services including Carragelose Nasal Spray, Carragelose Throat Spray, and Carragelose Lozenges. Carragelose operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Korneuburg, Austria
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Marinomed Biotech Ag
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Carragelose
Carragelose offers a comprehensive portfolio of products and services, including Carragelose Nasal Spray, Carragelose Throat Spray, and Carragelose Lozenges.
Spray that blocks viruses and allergens on nasal surfaces
Spray for protecting throat from respiratory viruses
Lozenges that provide mucosal protection and moisture
Funding Insights of Carragelose
Detailed funding history for Carragelose
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Carragelose
Carragelose has secured backing from 1 investor. Prominent investors backing the company include Nicox.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
Locked | Locked | Locked |
Investor details for Carragelose
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Carragelose
Investment portfolio details for Carragelose
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Carragelose
Detailed financials for Carragelose
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carragelose Comparisons
Peer comparison for Carragelose
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Carragelose
Carragelose operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
Detailed competitors of Carragelose
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carragelose
Complete news archive for Carragelose
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carragelose
Carragelose was founded in 2007.
Carragelose is headquartered in Korneuburg, Austria. It is registered at Korneuburg, Niederosterreich, Austria.
Founded in 2007 and based in Korneuburg, Austria, operations focus on the biotechnology sector for respiratory and infectious disease treatments. An anti-viral compound called Carragelose, derived from red seaweed, is produced in forms such as nasal sprays, throat sprays, and lozenges. This sulfated polymer targets viruses including the common cold, flu, and SARS-CoV-2 by preventing mucosal interactions and cell infections. Applications extend to the food industry as well.
Carragelose's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Carragelose offers Carragelose Nasal Spray, Carragelose Throat Spray, and Carragelose Lozenges.
Carragelose has 1 investor. Key investors include Nicox.